Spruce Biosciences Financials
SPRB Stock | USD 0.39 0.01 2.63% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 5.4 | 3.76 |
|
|
The essential information of the day-to-day investment outlook for Spruce Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Spruce Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Spruce Biosciences.
Net Income |
|
Spruce | Select Account or Indicator |
Please note, the presentation of Spruce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spruce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spruce Biosciences' management manipulating its earnings.
Spruce Biosciences Stock Summary
Spruce Biosciences competes with Inozyme Pharma, Day One, Terns Pharmaceuticals, Eledon Pharmaceuticals, and Hookipa Pharma. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California. Spruce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US85209E1091 |
CUSIP | 85209E109 |
Location | California; U.S.A |
Business Address | 611 Gateway Boulevard, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.sprucebiosciences.com |
Phone | 415 655 4168 |
Currency | USD - US Dollar |
Spruce Biosciences Key Financial Ratios
Return On Equity | -0.58 | ||||
Operating Margin | (15.63) % | ||||
Price To Sales | 2.26 X | ||||
Revenue | 10.09 M | ||||
Gross Profit | (28.96 M) |
Spruce Biosciences Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 162.9M | 126.5M | 85.6M | 103.9M | 119.5M | 89.5M | |
Other Current Liab | 3.3M | 5.7M | 9.3M | 14.3M | 16.5M | 17.3M | |
Net Tangible Assets | (30.6M) | 149.4M | 111.4M | 68.5M | 78.8M | 61.8M | |
Net Debt | (151.0M) | (36.6M) | (18.3M) | (91.7M) | (82.6M) | (78.4M) | |
Retained Earnings | (60.8M) | (103.1M) | (149.3M) | (197.2M) | (177.5M) | (168.6M) | |
Accounts Payable | 3.6M | 2.8M | 1.4M | 3.3M | 3.8M | 2.8M | |
Cash | 157.2M | 42.7M | 24.5M | 96.3M | 110.8M | 60.3M | |
Other Assets | 2.5K | 513K | 640K | 1.0 | 1.15 | 1.09 | |
Other Current Assets | 3.2M | 2.9M | 4.5M | 5.8M | 6.7M | 7.1M | |
Total Liab | 13.5M | 15.1M | 17.2M | 27.4M | 24.7M | 17.5M | |
Net Invested Capital | 153.9M | 116.2M | 73.4M | 79.8M | 91.8M | 69.6M | |
Total Current Assets | 160.4M | 91.9M | 83.6M | 102.2M | 117.5M | 82.0M | |
Net Working Capital | 150.6M | 83.0M | 71.2M | 77.7M | 89.4M | 70.6M | |
Long Term Debt | 1.9M | 4.9M | 3.3M | 1.7M | 1.5M | 2.4M | |
Short Term Debt | 2.8M | 360K | 1.8M | 1.9M | 2.2M | 1.8M |
Spruce Biosciences Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Net Interest Income | (323K) | (345K) | 1.1M | 3.8M | 4.4M | 4.6M | |
Interest Expense | 323K | 345K | 420K | 483K | 555.5K | 299.9K | |
Operating Income | (29.4M) | (42.1M) | (47.3M) | (52.0M) | (46.8M) | (49.1M) | |
Ebit | (29.2M) | (41.9M) | (45.8M) | (47.4M) | (42.7M) | (44.8M) | |
Research Development | 23.9M | 30.7M | 35.2M | 49.4M | 56.8M | 29.0M | |
Ebitda | (29.1M) | (41.6M) | (45.3M) | (47.4M) | (42.6M) | (44.8M) | |
Income Before Tax | (29.5M) | (42.3M) | (46.2M) | (47.9M) | (43.1M) | (45.3M) | |
Net Income | (30.0M) | (42.7M) | (45.1M) | (47.9M) | (43.1M) | (45.3M) | |
Income Tax Expense | 487K | 396K | (1.1M) | (97.9K) | (88.1K) | (83.7K) | |
Gross Profit | (102K) | (381K) | (429K) | (39.3M) | (35.4M) | (33.6M) | |
Cost Of Revenue | 102K | 381K | 429K | 49.4M | 56.8M | 59.7M |
Spruce Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Spruce Biosciences's current stock value. Our valuation model uses many indicators to compare Spruce Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spruce Biosciences competition to find correlations between indicators driving Spruce Biosciences's intrinsic value. More Info.Spruce Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Spruce Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spruce Biosciences' earnings, one of the primary drivers of an investment's value.Spruce Biosciences Systematic Risk
Spruce Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Spruce Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Spruce Biosciences correlated with the market. If Beta is less than 0 Spruce Biosciences generally moves in the opposite direction as compared to the market. If Spruce Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Spruce Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Spruce Biosciences is generally in the same direction as the market. If Beta > 1 Spruce Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Spruce Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spruce Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Spruce Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
At present, Spruce Biosciences' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Spruce Biosciences March 3, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Spruce Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Spruce Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Spruce Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Spruce Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Spruce Biosciences's daily price indicators and compare them against related drivers.
Information Ratio | (0.06) | |||
Maximum Drawdown | 28.37 | |||
Value At Risk | (5.26) | |||
Potential Upside | 5.26 |
Complementary Tools for Spruce Stock analysis
When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |